ERBB2 and breast carcinoma: By confirming cellular uptake in vitro, the authors demonstrated cytotoxic activity selectively enhanced in HER2-expressing breast cancer cells mediated by T cell activation compared with native vesicles still isolated by ultracentrifugation.